LongevityNext / Trials
Source-reviewed evidence, findings and limitations. Research intelligence, not treatment recommendations.
34 eligible records
Evidence reviewed
ASPREE compared aspirin 100 mg daily with placebo in 19,114 independent older adults. Over a median 4.7 years, the main disability-free survival outcome did not significantly improve, while major bleeding was more frequent. ASPREE-XT follows the same parent trial; later medication use was not continuously randomized.
Boundary: Main combined outcome not significantly improved; no individual stopping conclusion.
Evidence reviewed
JUPITER compared rosuvastatin 20 mg daily with placebo. This exploratory report concerns 5,695 participants aged 70 or older without cardiovascular disease, with LDL cholesterol below 130 mg/dL and elevated hsCRP (at least 2 mg/L). Fewer combined vascular events were reported; the mortality estimate remained uncertain.
Boundary: Exploratory subgroup with a selected inflammatory-risk profile; mortality remains uncertain.
Evidence reviewed
PROSPER compared pravastatin 40 mg daily with placebo in 5,804 adults aged 70-82 with previous vascular disease or risk factors, followed for an average of 3.2 years. Fewer combined vascular events were reported; the mixed population limits application to healthy older adults.
Boundary: Mixed prevention population; the overall estimate is not a primary-prevention-only result.
Evidence reviewed
Clarity AD: CLARITY AD showed less average cognitive-functional decline with lecanemab over 18 months, not recovery, with material ARIA and infusion-reaction risks.
Boundary: Both groups worsened; an 18-month randomized comparison does not demonstrate causal long-term extension benefit.
Evidence reviewed
DO-HEALTH: DO-HEALTH's selected methylation substudy found small omega-3-related changes in PhenoAge, GrimAge2 and DunedinPACE, not proof of clinical rejuvenation or lifespan gain.
Boundary: Clock response does not establish lifespan extension or whole-body rejuvenation.
Evidence reviewed
SELECT: SELECT demonstrated fewer major cardiovascular events with semaglutide in adults with established cardiovascular disease and overweight/obesity without diabetes, alongside greater treatment discontinuation.
Boundary: A secondary composite including macroalbuminuria is not proof of preventing kidney failure in all populations.
Evidence reviewed
PREDIMED: PREDIMED's withdrawn 2013 report must not serve as the current efficacy source; the 2018 replacement is a reanalysis of the same experiment after randomization deviations.
Boundary: The 2013 and 2018 articles cannot be counted as independent replication.
Evidence reviewed
US POINTER: US POINTER found a small additional cognitive-score improvement from structured versus self-guided multidomain lifestyle intervention, not an intervention-versus-inactivity effect.
Boundary: Cognitive-score improvement does not itself establish reduced dementia incidence.
Evidence reviewed
FINGER: FINGER's modest cognitive-score benefit and MAPT's adjusted null comparisons support an intervention-design-specific, not universal multidomain-prevention claim.
Boundary: Cognitive-score improvement does not itself establish reduced dementia incidence.
Evidence reviewed
Look AHEAD: Look AHEAD's intensive weight-loss lifestyle programme did not significantly reduce the primary cardiovascular composite in adults with type 2 diabetes.
Boundary: Mobility odds are not cardiovascular risk, survival or a universal weight-loss verdict.
Evidence reviewed
Diabetes Prevention Program / DPPOS: DPP/DPPOS shows sustained diabetes delay after lifestyle or metformin assignment, without an overall between-group aggregate microvascular benefit at 15 years.
Boundary: Existing MILES/MASTERS results and TAME's design-only status are not superseded.
Evidence reviewed
SPRINT MIND: SPRINT MIND did not demonstrate a statistically significant primary dementia reduction, while secondary MCI findings favored intensive blood-pressure control.
Boundary: Longer follow-up is not a fresh independent experiment or proof of dementia prevention.